Maryam Mooghali, MD, MSc @MaryamMooghali Twitter profile

Last Seen Profiles

@DrusillaCh49925

@ColU_Academy

@dukenus

@horiimikaTBS

@c_rajasekhar

@mod_mkh

@AlexBevens3

@lshakdmr

@enjay_green

@Lartedo

@AeneausL

@BinorRaja

@shinopitubuyaku

@stw_pdg

@Ariannnyy_

@purplbase

@taishi_DeFi

@DencAntone

@itzbhumi20

@tre_hinch

@coopbrown9

@MadisonRCook

@Aun_mihaku

@SophieleighHon1

@Rabbunnitt

@mulegiclifton

@stw_pdg

@muratceliktv

@GHamiltonOTF

@stwmaniax

@MongElrick

@jdjdhdjjdf

@DuniiaB

@Anticancerfund

@pseudohole

Maryam Mooghali, MD, MSc

@MaryamMooghali

7 months

Beyond excited and grateful to continue my journey at @YaleIMed ! I worked so hard, and finally this dream is coming true! I couldn’t have done this without the support of my family who were always there for me even from thousands of miles away and my exceptional mentors!

47

22

827

Maryam Mooghali, MD, MSc

@MaryamMooghali

1 year

Hi #MedTwitter ! I am Maryam, a postdoc researcher @YaleIMed & #IMG from Iran, applying to #InternalMedicine #Match2024 . I'm passionate about Medicine, Health Policy & Regulatory Science and love playing the piano, hiking & biking! Excited to connect with future peers & mentors!

15

18

394

Maryam Mooghali, MD, MSc

@MaryamMooghali

7 months

Such an honor!

Yale Internal Medicine

@YaleIMed

7 months

Congratulations to the newly matched residents in our Internal Medicine Traditional Residency Program! Welcome to @YaleMed @Yale @YNHH ! 🧵 #MatchDay2024 #Residency #MedTwitter #Match2024 @MarkDSiegel1 @TradIMYale

13

40

344

7

1

70

Maryam Mooghali, MD, MSc

@MaryamMooghali

9 months

It was an amazing opportunity to participate in the UCSF-Stanford CERSI Summit and Symposium and learn more about @US_FDA perspectives and many FDA-funded research work!

Yale CRRIT

@Yale_CRRIT

9 months

We are so proud of CRRIT Postdoctoral Fellow @MaryamMooghali for winning best poster awards at both the UCSF-Stanford CERSI Summit and CERSI Scientific Symposium for her CERSI-funded project. This recognition is so well deserved for all her hard work on this research endeavor.

0

3

21

2

0

30

Maryam Mooghali, MD, MSc

@MaryamMooghali

11 months

It was an amazing opportunity to share our recent @Yale_CRRIT study, evaluating the evidence supporting FDA’s Breakthrough Therapies, at @NAPCRG ! Another great collaboration with @reshmagar , @JoshuaDWallach , @jsross119

Yale CRRIT

@Yale_CRRIT

11 months

If you're at @NAPCRG this year, be sure to check out the new work of CRRIT postdoc @MaryamMooghali looking at the past decade of @US_FDA approved breakthrough therapies, their approval pathways, pivotal trial endpoints, & postmarketing requirements. @YaleMed 👏🏾👏🏾👏🏾

0

4

15

1

2

31

Maryam Mooghali, MD, MSc

@MaryamMooghali

1 year

Interested in learning more risk reclassification of medical devices? Check this @BMJSurgTech paper about the Lessons from @US_FDA 's 515 Program Initiative! These lessons could be used to advance access to medical devices while maintaining patient safety. @jsross119 @ktkadakia

0

9

28

Maryam Mooghali, MD, MSc

@MaryamMooghali

7 months

Super proud to a be a part of the amazing CRRIT family!

Yale CRRIT

@Yale_CRRIT

7 months

Thrilled that our amazing postdoc @MaryamMooghali will be staying here for a few more years, having matched here at @YaleIMed ! Congratulations, Maryam! #Match2024

1

4

29

1

27

Maryam Mooghali, MD, MSc

@MaryamMooghali

1 year

Such a great opportunity to be at #ASCO2023 and learn more about perspectives of FDA, healthcare providers, patient advocates, and industry on NCCN guidelines and accelerated approvals ! Huge thanks to @reshmagar , @JoshuaDWallach , @jsross119 , @TheWonkologist , and @SkydelJ !

0

5

15

Maryam Mooghali, MD, MSc

@MaryamMooghali

6 months

Check out our new study @BMJMedicine to learn about how NCCN guidelines recommend oncology drug treatments with @US_FDA accelerated approval. @Yale_CRRIT @reshmagar @jsross119 @JoshuaDWallach @SkydelJ @TheWonkologist

Characterization of accelerated approval status, trial endpoints and results, and recommendations...

Objectives To evaluate National Comprehensive Cancer Network (NCCN) guideline recommendations for oncology drug treatments that have been granted accelerated approval, and to determine whether...

bmjmedicine.bmj.com

1

3

14

Maryam Mooghali, MD, MSc

@MaryamMooghali

10 months

Led by Alissa Wong & @JoshuaDWallach , new @Yale_CRRIT study in JAMA showed that FDA oncology approvals had similar clinical development times regardless of whether their pivotal trials had adequate representation of female, older adult, Asian, Black, or Hispanic/Latino patients.

JAMA

@JAMA_current

10 months

Study evaluates whether FDA-approved novel cancer therapeutics supported by pivotal trials with adequate representation of minoritized groups were associated with slower clinical development times than those with inadequate representation.

0

6

17

0

14

Maryam Mooghali, MD, MSc

@MaryamMooghali

6 months

Our new study @BMJMedicine suggests that NCCN guidelines consistently provided information on postapproval trials that had confirmed clinical benefit. However, guideline recommendations were often not aligned with results of postapproval trials that had failed to confirm benefit.

1

10

Maryam Mooghali, MD, MSc

@MaryamMooghali

1 year

Undisclosed financial relationships with industry remain a major concern among US physician authors of clinical practice guidelines. Thankful for the recognition at the recent piece by @_GoozNews !! @jsross119 , @reshmagar , @laurarglick .

Financial conflicts of interest among US physician authors of 2020 clinical practice guidelines: a...

Objective To evaluate the prevalence and accuracy of industry-related financial conflict of interest (COI) disclosures among US physician guideline authors. Design Cross-sectional study. Setting...

bmjopen.bmj.com

Merrill Goozner

@_GoozNews

1 year

0

1

7

Maryam Mooghali, MD, MSc

@MaryamMooghali

6 months

@Yale_CRRIT @reshmagar @jsross119 @JoshuaDWallach @TheWonkologist @SkydelJ

0

2

Maryam Mooghali, MD, MSc

@MaryamMooghali

7 months

@FrnkEbrahimian @YaleIMed Thank you Faranak❤️

0

1

Maryam Mooghali, MD, MSc

@MaryamMooghali

7 months

@ArdestaniBahar @YaleIMed @YaleRadiology @khosravi_bardia @YaleIM_Chiefs @MarkDSiegel1 @MayoMrfa @StoriesImg @Inside_TheMatch Congratulations!!!

0

1

Maryam Mooghali, MD, MSc

@MaryamMooghali

1 year

@david__simon @aoeverhart @BMJSurgTech @US_FDA @jsross119 @ktkadakia Absolutely! The link is attached to the image:

Medical device risk (re)classification: lessons from the FDA’s 515 Program Initiative

The 1976 Medical Device Amendments to the Food, Drug and Cosmetic Act granted the US Food and Drug Administration (FDA) regulatory authority over medical devices. Congress intended for FDA’s review...

sit.bmj.com

0

1